Develops cell therapies for hematologic malignancies.
Jun 2026Revenue $10.0M/yrExpenses $120M/yr
No trendCash runway ≈ 1.2 years from Jun 2026
Figures by year
When will Caribou Biosciences be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $10.0M and expenses $120M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $11.2M | $160M | −$148M |
| Dec 2024 | $9.99M | $177M | −$167M |
| Dec 2023 | $34.5M | $151M | −$116M |
| Dec 2022 | $13.9M | $120M | −$106M |
| Dec 2021 | $9.60M | $76.6M | −$67.0M |
| Dec 2020 | $12.4M | $48.5M | −$36.1M |
| Dec 2019 | $5.79M | $40.1M | −$34.3M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.